NYSE$TEVA
Teva Pharmaceutical Industries ADR · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
Reported earnings for the quarter and year ended December 31, 2019.
Teva Pharmaceutical Industries Ltd. reported Q4 2019 results with revenues of $4.5 billion, a 1% increase compared to Q4 2018. GAAP earnings per share was $0.10 and non-GAAP EPS was $0.62. The company saw growth in sales of AUSTEDO, AJOVY, and certain respiratory products, which was partially offset by lower revenues from COPAXONE in North America.
- Completed two-year restructuring plan.
- Reduced cost base by more than $3 billion.
- Reduced net debt by more than $9 billion.
- Key growth products met major milestones, including the launch of AJOVY in Europe, continued strong growth for AUSTEDO, and the successful launch of Teva's first biosimilar TRUXIMA in North America.
Headline financials
Revenue & EPS history
Teva · Revenue · Quarterly
$4.47B
Revenue by segment
Teva · $1.76B total across 2 segments · Q4 2019
- Europe$1.18B—67.2%
- International Markets$578M—32.8%
Forward guidance
Teva provided its outlook for 2020, expecting revenues between $16.6 to $17.0 billion, Non-GAAP Operating Income between $4.0 to $4.4 billion, EBITDA between $4.5 to $4.9 billion, Non-GAAP EPS between $2.30 to $2.55, and Free cash flow between $1.8 to $2.2 billion.
Tailwinds
- Continued generic erosion; sales of approximately $1.2 billion from Global COPAXONE
- Continued increase in the U.S. sales to approximately $650 million from AUSTEDO
- Continued increase in sales to approximately $250 million from Global AJOVY
- Tax Rate 17% - 18%
- Moderate negative impact on revenues and operating income compared to 2019 from Foreign Exchange
Headwinds
- Global COPAXONE Continued generic erosion
- AUSTEDO Continued increase in the U.S. sales
- Global AJOVY Continued increase in sales
- Foreign Exchange Moderate negative impact on revenues and operating income compared to 2019
- CAPEX $0.6 billion
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2019
+0.3%
Avg return
Earnings day
+1.6%
Avg return
5 days after
+0.7%
Avg return
30 days after
51%
38 / 74 earnings
Positive
+27.1%
Q2 2022
Best reaction
-34.1%
Q2 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.1% | +11.9% | +11.7% | |
| Q4 2025 | +2.1% | +9.2% | +4.1% | |
| Q3 2025 | +20.4% | +18.6% | +39.1% | |
| Q2 2025 | +1.8% | -5.1% | +11.1% | |
| Q1 2025 | +8.9% | +11.4% | +10.2% | |
| Q4 2024 | -13.9% | -19.4% | -23.5% | |
| Q3 2024 | -6.8% | -7.5% | -7.7% | |
| Q2 2024 | +6.9% | +1.6% | +15.0% | |
| Q1 2024 | +14.7% | +21.0% | +20.6% | |
| Q4 2023 | +6.2% | +5.5% | +15.1% | |
| Q3 2023 | -3.0% | -2.4% | +8.6% | |
| Q2 2023 | +15.4% | +16.2% | +18.7% | |
| Q1 2023 | -9.8% | -11.3% | -19.5% | |
| Q4 2022 | -9.8% | -5.4% | -16.3% | |
| Q3 2022 | -3.3% | +3.7% | -1.1% | |
| Q2 2022 | +27.1% | +30.5% | +37.6% | |
| Q1 2022 | -2.3% | -8.1% | +11.6% | |
| Q4 2021 | +6.3% | +2.8% | -9.8% | |
| Q3 2021 | -7.0% | -1.7% | -9.6% | |
| Q2 2021 | +8.6% | +10.4% | +4.8% | |
| Q1 2021 | +2.6% | +4.2% | +0.3% | |
| Q4 2020 | -11.8% | -13.2% | -15.8% | |
| Q3 2020 | -1.0% | +4.5% | +11.6% | |
| Q2 2020 | +3.0% | +0.6% | -22.1% | |
| Q1 2020 | +7.7% | +9.0% | +22.5% | |
| Q4 2019 | +1.9% | -0.9% | -31.9% | |
| Q3 2019 | +14.8% | +18.6% | +22.5% | |
| Q2 2019 | +3.3% | -0.6% | -0.7% | |
| Q1 2019 | -0.3% | -4.1% | -43.2% | |
| Q4 2018 | -9.6% | -6.0% | -13.7% | |
| Q3 2018 | +13.1% | +15.6% | +7.8% | |
| Q2 2018 | -7.1% | -2.5% | -4.0% | |
| Q1 2018 | -4.1% | +1.6% | +17.7% | |
| Q4 2017 | -10.7% | -11.2% | -8.0% | |
| Q3 2017 | -18.7% | -16.6% | +8.8% | |
| Q2 2017 | -34.1% | -16.2% | -39.4% | |
| Q1 2017 | +1.7% | +1.3% | -3.6% | |
| Q4 2016 | +8.4% | +9.4% | +6.7% | |
| Q3 2016 | -7.2% | -6.0% | -10.5% | |
| Q2 2016 | +1.2% | -6.2% | -8.8% | |
| Q1 2016 | +5.2% | +1.7% | +10.8% | |
| Q4 2015 | -2.0% | — | — | |
| Q3 2015 | -5.1% | — | — | |
| Q2 2015 | -2.6% | — | — | |
| Q1 2015 | +0.1% | — | — | |
| Q3 2014 | +3.6% | — | — | |
| Q4 2014 | +2.0% | — | — | |
| Q2 2014 | -1.6% | — | — | |
| Q1 2014 | +2.0% | — | — | |
| Q4 2013 | -1.9% | — | — | |
| Q3 2013 | -1.5% | — | — | |
| Q2 2013 | -2.0% | — | — | |
| Q1 2013 | +1.0% | — | — | |
| Q4 2012 | +1.4% | — | — | |
| Q3 2012 | +2.6% | — | — | |
| Q2 2012 | -3.3% | — | — | |
| Q1 2012 | -5.4% | — | — | |
| Q4 2011 | +2.5% | — | — | |
| Q3 2011 | +7.0% | — | — | |
| Q2 2011 | +1.9% | — | — | |
| Q1 2011 | +5.6% | — | — | |
| Q4 2010 | +0.4% | — | — | |
| Q3 2010 | +0.3% | — | — | |
| Q2 2010 | -3.4% | — | — | |
| Q1 2010 | +0.9% | — | — | |
| Q4 2007 | +1.2% | — | — | |
| Q4 2009 | +1.2% | — | — | |
| Q3 2008 | -1.4% | — | — | |
| Q3 2009 | -1.4% | — | — | |
| Q2 2008 | -0.8% | — | — | |
| Q2 2009 | -0.8% | — | — | |
| Q1 2009 | -0.6% | — | — | |
| Q1 2008 | -0.6% | — | — | |
| Q4 2008 | -0.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro